Citation de Invité le 21 novembre 2024, 9 h 00 min

The approval is based on results from the KEYNOTE 355 trial, which showed that Keytruda along with chemotherapy offered better progression free survival than chemotherapy alone as the first treatment for PD L1 positive, metastatic triple negative breast cancer or PD L1 positive, triple negative breast cancer that has come back recurred in the breast area but can t be removed with surgery [url=https://fastpriligy.top/]priligy review youtube[/url]